Document And Entity Information
Document And Entity Information - shares | 9 Months Ended | |
Mar. 31, 2018 | Apr. 22, 2018 | |
Document And Entity Information [Abstract] | ||
Document Type | 10-Q | |
Amendment Flag | false | |
Document Period End Date | Mar. 31, 2018 | |
Document Fiscal Year Focus | 2,018 | |
Document Fiscal Period Focus | Q3 | |
Trading Symbol | rmd | |
Entity Registrant Name | RESMED INC | |
Entity Central Index Key | 943,819 | |
Current Fiscal Year End Date | --06-30 | |
Entity Filer Category | Large Accelerated Filer | |
Entity Common Stock, Shares Outstanding | 142,738,359 |
Condensed Consolidated Balance
Condensed Consolidated Balance Sheets - USD ($) $ in Thousands | Mar. 31, 2018 | Jun. 30, 2017 |
Current assets: | ||
Cash and cash equivalents | $ 704,281 | $ 821,935 |
Accounts receivable, net of allowance for doubtful accounts of $17,514 and $11,150 at March 31, 2018 and June 30, 2017, respectively | 498,425 | 450,530 |
Inventories (note 2) | 288,703 | 268,319 |
Prepaid expenses and other current assets | 112,997 | 103,219 |
Total current assets | 1,604,406 | 1,644,003 |
Non-current assets: | ||
Property, plant and equipment, net (note 3) | 397,981 | 394,241 |
Goodwill (note 4) | 1,080,948 | 1,064,874 |
Other intangible assets, net (note 5) | 228,223 | 261,800 |
Deferred income taxes | 46,282 | 61,503 |
Prepaid taxes and other non-current assets | 176,368 | 42,066 |
Total non-current assets | 1,929,802 | 1,824,484 |
Total assets | 3,534,208 | 3,468,487 |
Current liabilities: | ||
Accounts payable | 88,157 | 92,763 |
Accrued expenses | 190,733 | 186,295 |
Deferred revenue | 58,001 | 51,918 |
Short-term income taxes payable (note 7) | 124,569 | 29,150 |
Total current liabilities | 461,460 | 360,126 |
Non-current liabilities: | ||
Deferred revenue | 66,834 | 53,235 |
Deferred income taxes | 12,758 | 13,822 |
Other long-term liabilities | 2,473 | 2,427 |
Long-term debt, net (note 9) | 810,000 | 1,078,611 |
Long-term income taxes payable (note 7) | 113,719 | |
Total non-current liabilities | 1,005,784 | 1,148,095 |
Total liabilities | 1,467,244 | 1,508,221 |
Commitments and contingencies (note 13) | ||
Stockholders’ equity: (note 10) | ||
Preferred stock, $0.01 par value, 2,000,000 shares authorized; none issued | ||
Common stock, $0.004 par value, 350,000,000 shares authorized; 184,109,932 issued and 142,723,698 outstanding at March 31, 2018 and 183,260,958 issued and 142,174,724 outstanding at June 30, 2017 | 571 | 569 |
Additional paid-in capital | 1,424,027 | 1,379,130 |
Retained earnings | 2,372,487 | 2,316,237 |
Treasury stock, at cost, 41,386,234 shares at March 31, 2018 and 41,086,234 shares at June 30, 2017 | (1,574,508) | (1,546,611) |
Accumulated other comprehensive loss | (155,613) | (189,059) |
Total stockholders' equity | 2,066,964 | 1,960,266 |
Total liabilities and stockholders' equity | $ 3,534,208 | $ 3,468,487 |
Condensed Consolidated Balance3
Condensed Consolidated Balance Sheets (Parenthetical) - USD ($) $ in Thousands | Mar. 31, 2018 | Jun. 30, 2017 |
Condensed Consolidated Balance Sheets [Abstract] | ||
Accounts receivable, net allowance for doubtful accounts | $ 17,514 | $ 11,150 |
Preferred stock, par value | $ 0.01 | $ 0.01 |
Preferred stock, shares authorized | 2,000,000 | 2,000,000 |
Preferred stock, shares issued | 0 | 0 |
Common stock, par value | $ 0.004 | $ 0.004 |
Common stock, shares authorized | 350,000,000 | 350,000,000 |
Common stock, shares issued | 184,109,932 | 183,260,958 |
Common stock, shares outstanding | 142,723,698 | 142,174,724 |
Treasury stock, shares held | 41,386,234 | 41,086,234 |
Condensed Consolidated Statemen
Condensed Consolidated Statements Of Income - USD ($) shares in Thousands, $ in Thousands | 3 Months Ended | 9 Months Ended | ||
Mar. 31, 2018 | Mar. 31, 2017 | Mar. 31, 2018 | Mar. 31, 2017 | |
Condensed Consolidated Statements Of Income [Abstract] | ||||
Net revenue | $ 591,634 | $ 514,204 | $ 1,716,566 | $ 1,510,051 |
Cost of sales (excluding amortization of acquired intangible assets) | 247,339 | 214,490 | 716,874 | 632,082 |
Gross profit | 344,295 | 299,714 | 999,692 | 877,969 |
Operating expenses: | ||||
Selling, general and administrative | 147,893 | 137,864 | 443,559 | 406,028 |
Research and development | 37,434 | 35,130 | 115,492 | 107,761 |
Amortization of acquired intangible assets | 11,673 | 11,378 | 34,772 | 34,809 |
Restructuring expenses (note 15) | 10,922 | 7,945 | 10,922 | 12,358 |
Litigation settlement expenses | 8,500 | |||
Acquisition related expenses | 10,076 | |||
Total operating expenses | 207,922 | 192,317 | 604,745 | 579,532 |
Income from operations | 136,373 | 107,397 | 394,947 | 298,437 |
Other income (loss), net: | ||||
Interest income | 4,228 | 4,425 | 13,677 | 14,490 |
Interest expense | (7,719) | (7,336) | (22,873) | (22,331) |
Other, net | (2,739) | 3,504 | (5,357) | 6,525 |
Total other income (loss), net | (6,230) | 593 | (14,553) | (1,316) |
Income before income taxes | 130,143 | 107,990 | 380,394 | 297,121 |
Income taxes | 20,018 | 20,167 | 174,617 | 56,449 |
Net income | $ 110,125 | $ 87,823 | $ 205,777 | $ 240,672 |
Basic earnings per share (note 11) | $ 0.77 | $ 0.62 | $ 1.44 | $ 1.70 |
Diluted earnings per share (note 11) | 0.76 | 0.62 | 1.43 | 1.69 |
Dividend declared per share | $ 0.35 | $ 0.33 | $ 1.05 | $ 0.99 |
Basic shares outstanding (000's) | 142,898 | 141,714 | 142,688 | 141,266 |
Diluted shares outstanding (000's) | 143,985 | 142,724 | 143,895 | 142,363 |
Condensed Consolidated Stateme5
Condensed Consolidated Statements Of Comprehensive Income - USD ($) $ in Thousands | 3 Months Ended | 9 Months Ended | ||
Mar. 31, 2018 | Mar. 31, 2017 | Mar. 31, 2018 | Mar. 31, 2017 | |
Condensed Consolidated Statements Of Comprehensive Income [Abstract] | ||||
Net income | $ 110,125 | $ 87,823 | $ 205,777 | $ 240,672 |
Other comprehensive income (loss): | ||||
Foreign currency translation (loss) gain adjustments | (7,393) | 86,882 | 33,446 | 9,557 |
Comprehensive income (loss) | $ 102,732 | $ 174,705 | $ 239,223 | $ 250,229 |
Condensed Consolidated Stateme6
Condensed Consolidated Statements Of Cash Flows - USD ($) $ in Thousands | 9 Months Ended | |
Mar. 31, 2018 | Mar. 31, 2017 | |
Cash flows from operating activities: | ||
Net income | $ 205,777 | $ 240,672 |
Adjustment to reconcile net income to net cash provided by operating activities: | ||
Depreciation and amortization | 88,256 | 83,989 |
Stock-based compensation costs | 35,933 | 34,263 |
Impairment of cost-method investments | 3,620 | 588 |
Changes in fair value of business combination contingent consideration (note 12) | 383 | 10,076 |
Payment of business combination contingent consideration (note 12) | (8,460) | |
Changes in operating assets and liabilities, net of effect of acquisitions: | ||
Accounts receivable | (39,421) | (32,793) |
Inventories | (11,146) | (38,146) |
Prepaid expenses, net deferred income taxes and other current assets | (72,332) | (28,554) |
Accounts payable, accrued expenses and other | 164,540 | 12,105 |
Net cash provided by operating activities | 375,610 | 273,740 |
Cash flows from investing activities: | ||
Purchases of property, plant and equipment | (44,961) | (43,857) |
Patent registration costs | (6,743) | (6,980) |
Business acquisitions, net of cash acquired | (482) | (3,394) |
Investment in cost-method investments | (6,445) | (6,464) |
Proceeds (payments) on maturity of foreign currency contracts | (4,667) | 10,085 |
Net cash used in investing activities | (63,298) | (50,610) |
Cash flows from financing activities: | ||
Proceeds from issuance of common stock, net | 9,603 | 15,255 |
Purchases of treasury stock | (27,897) | |
Payment of business combination contingent consideration (note 12) | (205) | (11,682) |
Proceeds from borrowings, net of borrowing costs | 120,000 | 350,000 |
Repayment of borrowings | (390,000) | (355,000) |
Dividend paid | (149,527) | (139,546) |
Net cash used in financing activities | (438,026) | (140,973) |
Effect of exchange rate changes on cash | 8,060 | 13,719 |
Net increaase (decrease) in cash and cash equivalents | (117,654) | 95,876 |
Cash and cash equivalents at beginning of period | 821,935 | 731,434 |
Cash and cash equivalents at end of period | 704,281 | 827,310 |
Supplemental disclosure of cash flow information: | ||
Income taxes paid, net of refunds | 75,119 | 76,721 |
Interest paid | 22,873 | 20,480 |
Fair value of assets acquired, excluding cash | 290 | 5,811 |
Liabilities assumed | (818) | |
Goodwill on acquisition | 247 | (2,436) |
Deferred payments | (55) | 837 |
Total cash component of purchase price | $ 482 | $ 3,394 |
Summary Of Significant Accounti
Summary Of Significant Accounting Policies | 9 Months Ended |
Mar. 31, 2018 | |
Summary Of Significant Accounting Policies [Abstract] | |
Summary Of Significant Accounting Policies | (1) Summary of Significant Accounting Policies  Organization and Basis of Presentation  ResMed Inc. (referred to herein as “we”, “us”, “our” or the “Company”) is a Delaware corporation formed in March 1994 as a holding company for the ResMed Group. Through our subsidiaries, we design, manufacture and market equipment for the diagnosis and treatment of sleep-disordered breathing and other respiratory disorders, including obstructive sleep apnea. Our manufacturing operations are located in Australia, Singapore, Malaysia, France, China and the United States. Major distribution and sales sites are located in the United States, Germany, France, the United Kingdom, Switzerland, Australia, Japan, China, Norway and Sweden.  The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (“U.S. GAAP”) for interim financial information and with the instructions to Form 10-Q and the rules of the U.S. Securities and Exchange Commission (“SEC”). Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. In the opinion of management, all necessary adjustments, which consisted only of normal recurring items, have been included in the accompanying financial statements to present fairly the results of the interim periods. The results of operations for the interim periods presented are not necessarily indicative of the results that may be expected for the year ending June 30, 2018 .  The condensed consolidated financial statements for the three and nine months ended March 31, 2018 and March 31, 2017 are unaudited and should be read in conjunction with the consolidated financial statements and notes thereto included in our Form 10-K for the year ended June 30, 2017 .  Revenue Recognition  We generally record revenue on product sales at the time of shipment, which is when title transfers to the customer. We do not record revenue on product sales which require customer acceptance until we receive acceptance. We initially defer service revenue received in advance from service contracts and recognize that deferred revenue ratably over the life of the service contract. We initially defer revenue we receive in advance from rental unit contracts and recognize that deferred revenue ratably over the life of the rental contract. Otherwise, we recognize revenue from rental unit contracts ratably over the life of the rental contract. We include in revenue freight charges we bill to customers. We charge all freight-related expenses to cost of sales. Taxes assessed by government authorities that are imposed on and concurrent with revenue-producing transactions, such as sales and value added taxes, are excluded from revenue.  We do not recognize revenues to the extent that we offer a right of return or other recourse with respect to the sale of our products, other than returns for product defects or other warranty claims, nor do we recognize revenues if we offer variable sale prices for subsequent events or activities. However, as part of our sales processes, we may provide upfront discounts for large orders, one-time special pricing to support new product introductions, sales rebates for centralized purchasing entities or price-breaks for regular order volumes. We record the costs of all such programs as an adjustment to revenue at the time the related revenue is recognized. Our products are predominantly therapy-based equipment and require no installation. Therefore, we have no installation obligations. For multiple-element arrangements, we allocate arrangement consideration to the deliverables by use of the relative selling price method. The selling price used for each deliverable is based on vendor–specific objective evidence.  We also generate revenue from time-based licensing of our software and associated services. In most instances, revenue is generated under sales agreements with multiple elements comprising subscription fees and professional services, which typically have contract terms of one to three years. We evaluate each element in these multiple-element arrangements to determine whether they represent a separate unit of accounting and recognize each element as the services are performed.  Provision for Warranty  We provide for the estimated cost of product warranties at the time the related revenue is recognized. We determine the amount of this provision by using a financial model, which takes into consideration actual historical expenses and potential risks associated with our different products. We use this financial model to calculate the future probable expenses related to warranty and the required level of the warranty provision. Although we engage in product improvement programs and processes, our warranty obligation is affected by product failure rates and costs incurred to correct those product failures. Should actual product failure rates or estimated costs to repair those product failures differ from our estimates, we would be required to revise our estimated warranty provision.  New Accounting Pronouncements  (a) Recently issued accounting standards not yet adopted  ASU No. 2014-09, “Revenue from Contracts with Customers” In May, 2014, the Financial Accounting Standards Board (the “FASB”) issued Accounting Standards Update (“ASU”), ASU No. 2014-09, “Revenue from Contracts with Customers” (Topic 606), which requires an entity to recognize the amount of revenue to which it expects to be entitled for the transfer of promised goods or services to customers. Since its initial release, the FASB has issued several amendments to the standard, which include clarification of accounting guidance related to identification of performance obligations, intellectual property licenses, and principal vs. agent considerations. ASU 2014-09 and all subsequent amendments (collectively, the “new revenue recognition standards”) will replace most existing revenue recognition guidance in U.S. GAAP when it becomes effective. The guidance also requires improved disclosures on the nature, amount, timing, and uncertainty of revenue that is recognized.  We formed an implementation team in fiscal year June 30, 2017 to oversee adoption of the new revenue recognition standards. The implementation team completed the diagnostic phase of its project which has included assessing the composition and detailed review of our contract portfolio and selection of sample contracts for assessment. There are a number of steps in the team’s project plan that remain to be completed including: finalizing contract reviews, evaluating the impact, and working through required changes to systems, business processes and controls to support the adoption of the new revenue recognition standards. We expect there will be changes to our accounting policies to align with terminology and concepts in the new revenue recognition standards as well as increased disclosures relating to our revenue streams, contract-related balances and contract details.  The new revenue recognition standard is effective for us beginning in the first quarter of the fiscal year ending June 30, 2019 and early application is permitted for annual or interim periods beginning after December 15, 2016. The new guidance can be applied retrospectively to each prior reporting period presented, or retrospectively with the cumulative effect of the change recognized at the date of the initial application. Assuming the impact is not material, we expect to adopt the new revenue recognition standards using the modified retrospective method with an adjustment to beginning retained earnings for the cumulative effect of the change.  ASU No. 2016-01, "Financial Instruments - Overall" In January 2016, the FASB issued Accounting Standards Update ASU No. 2016-01, "Financial Instruments - Overall" (Topic 825-10). The amendments address certain aspects of recognition, measurement, presentation, and disclosure of financial instruments, and require equity securities to be measured at fair value with changes in fair value recognized through net income. The amendments also simplify the impairment assessment of equity investments without readily determinable fair values by requiring a qualitative assessment for impairment quarterly at each reporting period. The amendments in ASU 2016-01 will be effective for our first quarter of the fiscal year ending June 30, 2019. An entity should apply the amendments by means of a cumulative-effect adjustment to the balance sheet as of the beginning of the fiscal year of adoption, with prospective adoption of the amendments related to equity securities without readily determinable fair values existing as of the date of adoption. We are currently assessing the impact as this standard will be relevant for our Cost-Method Investments.  ASU No. 2016-02, “Leases” In February 2016, the FASB issued Accounting Standard Update ASU No. 2016-02, “Leases” (Topic 842). Under the new guidance , lessees are required to recognize a right-of-use asset and a lease liability on the balance sheet for all leases, other than those that meet the definition of a short-term lease. This update will establish a lease asset and lease liability by lessees for those leases classified as operating under current GAAP. Leases will be classified as either operating or finance under the new guidance. Operating leases will result in straight-line expense in the income statement, similar to current operating leases, and finance leases will result in more expense being recognized in the earlier years of the lease term, similar to current capital leases. For lessors, the update will more closely align lease accounting to comparable guidance in the new revenue standards described.  The new standard is effective for us beginning in the first quarter of the fiscal year ending June 30, 2020 and early application is permitted. ASU 2016-02 will be adopted on a modified retrospective transition basis for leases existing at, or entered into after, the beginning of the earliest comparative period presented in the financial statements. We are currently evaluating the impact of this standard on our consolidated financial statements and expect to commence an implementation project during the fiscal year ending June 30, 2018. While the formal impact assessment has not commenced, we expect this amendment will affect the way we account for operating leases where we are the lessee (as described above), require reassessment of how we account for revenue where we are the lessor and will result in increased disclosures for all lease arrangements.  ASU No. 2016-16, “Income Taxes: Intra-Entity Transfers of Assets Other Than Inventory” In October 2016, the FASB issued Accounting Standard Update ASU No. 2016-16, “Income Taxes: Intra-Entity Transfers of Assets Other Than Inventory” (Topic 740). Under the new guidance, an entity is required to recognize the income tax consequences of an intra-entity transfer of an asset other than inventory when the transfer occurs and eliminates the exception for an intra-entity transfer of an asset other than inventory. ASU 2016-16 will be effective for the first quarter of our fiscal year ending June 30, 2019 and is required to be adopted on a modified retrospective basis, with a cumulative-effect adjustment recorded directly to retained earnings for intra-entity transfers that occur before the adoption date. Based on this adoption method , we expect to record a cumulative-effect adjustment directly to retained earnings and a reduction in prepaid taxes of approximately $60.0 million on July 1, 2018.  (b) Recently adopted accounting pronouncements  We have not adopted any new accounting pronouncements during the nine months ended March 31, 2018 . |
Inventories
Inventories | 9 Months Ended |
Mar. 31, 2018 | |
Inventories [Abstract] | |
Inventories | (2) Inventories  Inventories were comprised of the following at March 31, 2018 and June 30, 2017 (in thousands):   March 31, 2018 June 30, 2017  Raw materials $ 86,692 $ 75,658  Work in progress 3,787 4,297  Finished goods 198,224 188,364  Total inventories $ 288,703 $ 268,319 |
Property, Plant And Equipment
Property, Plant And Equipment | 9 Months Ended |
Mar. 31, 2018 | |
Property, Plant And Equipment [Abstract] | |
Property, Plant And Equipment | (3) Property, Plant and Equipment  Property, plant and equipment were comprised of the following as of March 31, 2018 and June 30, 2017 (in thousands):   March 31, 2018 June 30, 2017  Machinery and equipment $ 245,339 $ 230,632  Computer equipment 164,969 154,032  Furniture and fixtures 52,180 47,074  Vehicles 7,904 7,667  Clinical, demonstration and rental equipment 97,594 86,024  Leasehold improvements 39,240 35,932  Land 55,317 55,311  Buildings 233,978 233,868  896,521 850,540  Accumulated depreciation and amortization (498,540) (456,299)  Property, plant and equipment, net $ 397,981 $ 394,241 |
Goodwill
Goodwill | 9 Months Ended |
Mar. 31, 2018 | |
Goodwill And Other Intangible Assets [Abstract] | |
Goodwill | (4) Goodwill Changes in the carrying amount of goodwill for nine months ended March 31, 2018 , and March 31, 2017 , were as follows (in thousands):   Nine Months Ended March 31,  2018 2017  Balance at the beginning of the period $ 1,064,874 $ 1,059,245  Business acquisition 247 (2,436)  Foreign currency translation adjustments 15,827 (6,726)  Balance at the end of the period $ 1,080,948 $ 1,050,083 |
Other Intangible Assets
Other Intangible Assets | 9 Months Ended |
Mar. 31, 2018 | |
Goodwill And Other Intangible Assets [Abstract] | |
Other Intangible Assets | (5) Other Intangible Assets Other intangible assets were comprised of the following as of March 31, 2018 and June 30, 2017 (in thousands):    March 31, 2018 June 30, 2017  Developed/core product technology $ 208,134 $ 206,258  Accumulated amortization (111,277) (93,079)  Developed/core product technology, net 96,857 113,179  Trade names 48,969 48,768  Accumulated amortization (15,515) (10,894)  Trade names, net 33,454 37,874  Non-compete agreements 3,698 3,660  Accumulated amortization (2,576) (2,236)  Non-compete agreements, net 1,122 1,424  Customer relationships 124,552 122,458  Accumulated amortization (51,036) (40,050)  Customer relationships, net 73,516 82,408  In-process research and development - 4,100  Accumulated amortization - -  In-process research and development, net - 4,100  Patents 93,139 85,780  Accumulated amortization (69,865) (62,965)  Patents, net 23,274 22,815  Total other intangibles, net $ 228,223 $ 261,800  Intangible assets consist of developed/core product technology, trade names, non-compete agreements, customer relationships, and patents, which we amortize over the estimated useful life of the assets, generally between two and fifteen years. There are no expected residual values related to these intangible assets. In-process research and development is amortized over the estimated useful life of the assets, once the research and development efforts are completed. |
Cost-Method Investments
Cost-Method Investments | 9 Months Ended |
Mar. 31, 2018 | |
Cost-Method Investments [Abstract] | |
Cost-Method Investments | (6) Cost-Method Investments  The aggregate carrying amount of our cost-method investments at March 31, 2018 and June 30, 2017 , was $41.1 million and $38.3 million, respectively, and is included in the non-current balance of other assets on the condensed consolidated balance sheets.  We periodically evaluate the carrying value of our cost-method investments, when events and circumstances indicate that the carrying amount of an asset may not be recovered. We estimate the fair value of our cost-method investments to assess whether impairment losses shall be recorded using Level 3 inputs. These investments include our holdings in privately held service and research companies that are not exchange traded and therefore not supported with observable market prices. However, these investments are valued by reference to their net asset values that can be market supported and unobservable inputs including future cash flows. During the nine months ended March 31, 2018 and 2017 , we recognized $3.6 million and $0.6 million, respectively, of impairment losses related to our cost-method investments. We have determined, after the impairment charge, that the fair value of our remaining investments exceed their carrying values.  The following table shows a reconciliation of the changes in our cost-method investments during the nine months ended March 31, 2018 and March 31, 2017 (in thousands):   Nine Months Ended March 31,  2018 2017  Balance at the beginning of the period $ 38,324 $ 33,815  Investments 6,445 6,464  Impairment of cost-method investments (3,620) (588)  Balance at the end of the period $ 41,149 $ 39,691 |
Income Taxes
Income Taxes | 9 Months Ended |
Mar. 31, 2018 | |
Income Taxes [Abstract] | |
Income Taxes | (7) Income Taxes  In accordance with ASC 740 Income Taxes , each interim reporting period is considered integral to the annual period, and tax expense is measured using an estimated annual effective tax rate. An entity is required to record income tax expense each quarter based on its annual effective tax rate estimated for the full fiscal year and use that rate to provide for income taxes on a current year-to-date basis, adjusted for discrete taxable events that occur during the interim period.  Our income tax returns are based on calculations and assumptions subject to audit by various tax authorities. In addition, the calculation of our tax liabilities involves dealing with uncertainties in the application of complex tax laws. We regularly assess the potential outcomes of examinations by tax authorities in determining the adequacy of our provision for income taxes. Any final assessment resulting from tax audits may result in material changes to our past or future taxable income, tax payable or deferred tax assets, and may require us to pay penalties and interest that could materially adversely affect our financial results .  In connection with the audit by the Australian Taxation Office (“ATO”) for the tax years 2009 to 2013 , we received Notices of Amended Assessments in March 2018. Based on these assessments, the ATO is asserting that we owe $151.7 million in additional income tax and $38.4 million in accrued interest. In April 2018, we agreed to a payment arrangement with the ATO, whereby an amount of $75.9 million was paid by us in April 2018, with the remaining amounts due only if we are unsuccessful in defending our position. We do not agree with the ATO’s assessments and intend to pursue administrative and legal steps to defend our position. We continue to believe we are more likely than not to be successful in defending our position and therefore we have not recognized any income tax expense in relation to these assessments. At March 31, 2018, we have recorded a liability of $75.9 million in short-term income taxes payable , which was offset by an equivalent receivable recorded in p repaid taxes and other non-current assets , as we ultimately expect this will be refunded by the ATO .  Our income tax expense, short-term income taxes payable and long-term income taxes payable were impacted by charges associated with the Tax Cuts and Jobs Act (“U.S. legislation”) enacted on December 22, 2017, which resulted in additional income tax expense of $132.2 million during the nine months ended March 31, 2018. Specifically, the income tax expense includes both the transition tax imposed on our accumulated foreign earnings, which resulted in additional income tax expense of $5.6 million recorded during the three months ended March 31, 2018, and $125.5 million during the nine months ended March 31, 2018 and, and the write down in the carrying value of our net deferred tax assets due to the lower corporate tax rate, which resulted in additional income tax expense of $Nil and $6.7 million recorded in the three and nine months ended March 31, 2018 , respectively .  On December 22, 2017, the SEC issued guidance under Staff Accounting Bulletin No. 118, Income Tax Accounting Implications of the Tax Cuts and Jobs Act (“SAB 118”) directing taxpayers to consider the impact of the U.S. legislation as “provisional” when it does not have the necessary information available, prepared or analyzed (including computations) in reasonable detail to complete its accounting for the change in tax law. In accordance with SAB 118, the additional estimated income tax of $132.2 million represents our best estimate based on interpretation of the U.S. legislation as we are still accumulating data to finalize the underlying calculations, or in certain cases, the U.S. Treasury is expected to issue further guidance on the application of certain provisions of the U.S. legislation. In accordance with SAB 118, the additional estimated income tax of $132.2 million is considered provisional and will be finalized before December 22, 2018. |
Product Warranties
Product Warranties | 9 Months Ended |
Mar. 31, 2018 | |
Product Warranties [Abstract] | |
Product Warranties | (8) Product Warranties  Changes in the liability for warranty costs, which is included in accrued expenses in our condensed consolidated balance sheets, for the nine months ended March 31, 2018 and March 31, 2017 , are as follows (in thousands):    Nine Months Ended March 31,  2018 2017  Balance at the beginning of the period $ 19,558 $ 15,043  Warranty accruals for the period 13,041 15,237  Warranty costs incurred for the period (13,135) (10,085)  Foreign currency translation adjustments 485 (8)  Balance at the end of the period $ 19,949 $ 20,187 |
Debt
Debt | 9 Months Ended |
Mar. 31, 2018 | |
Debt [Abstract] | |
Debt | (9) Debt Debt at March 31, 2018 and June 30, 2017 consisted of the following (in thousands):   March 31, 2018 June 30, 2017  Long-term debt $ 810,000 $ 1,080,000  Deferred borrowing costs - (1,389)  Long-term debt, net $ 810,000 $ 1,078,611  Total debt $ 810,000 $ 1,078,611  Credit Facility  On October 31, 2013, we entered into a revolving credit agreement, as borrower, with lenders, including Union Bank, N.A., as administrative agent, joint lead arranger, swing line lender and letters of credit issuer, and HSBC Bank USA, National Association, as syndication agent and joint lead arranger, providing for a revolving credit facility of $700.0 million, with an uncommitted option to increase the revolving credit facility by an additional $300.0 million. On April 4, 2016, in connection with our acquisition of Brightree LLC (“Brightree”), we entered into a first amendment to the revolving credit agreement to increase the size of the revolving credit facility from $700.0 million to $1.0 billion, with an uncommitted option to increase the revolving credit facility by an additional $300.0 million, and to make other modifications to provide for the acquisition of Brightree. On January 9, 2017, we entered into a second amendment to our agreement with our existing lenders, including MUFG Union Bank, N.A. as successor in interest to Union Bank, N.A., as Administrative Agent, Joint Lead Arranger, Swing Line Lender and L/C Issuer; and HSBC Bank USA, National Association, as Syndication Agent and Joint Lead Arranger. The second amendment, among other things, increased the size of our senior unsecured revolving credit facility from $1.0 billion to $1.3 billion, with an uncommitted option to increase the revolving credit facility by an additional $300.0 million. The credit facility was due to terminate on October 31, 2018 , when all unpaid principal and interest under the loans were to be repaid. The outstanding principal amount due under the credit facility was subject to interest at a rate equal to LIBOR plus 1.0% to 2.0% (depending on the then-applicable leverage ratio). At March 31, 2018 , the interest rate that was being charged on the outstanding principal amount was 3.0% . A commitment fee of 0.15% to 0.25% (depending on the then-applicable leverage ratio) applies on the unused portion of the credit facility. The credit facility also includes a $25.0 million sublimit for letters of credit.  Our obligations under the revolving credit agreement were unsecured but were guaranteed by certain of our direct and indirect U. S. subsidiaries, including ResMed Corp., ResMed Motor Technologies Inc., Birdie Inc., Inova Labs, Inc., Brightree, Brightree Services LLC, Brightree Home Health & Hospice LLC and Strategic AR LLC, under an unconditional guaranty. The credit agreement contains customary covenants, including certain financial covenants and an obligation that we maintain certain financial ratios, including a maximum leverage ratio of funded debt to EBITDA (as defined in the credit agreement) and an interest coverage ratio. At March 31, 2018 , there was $810.0 million outstanding under the revolving credit facility.  On April 17, 2018, we entered into an amended and restated credit agreement and into a new unsecured term credit agreement. For a description of these agreements, see note 16—Subsequent Events. Due to the subsequent refinancing of the existing debt , the outstanding balance at March 31, 2018 has been classified as long-term debt. |
Stockholders' Equity
Stockholders' Equity | 9 Months Ended |
Mar. 31, 2018 | |
Stockholders' Equity [Abstract] | |
Stockholders' Equity | (10) Stockholders’ Equity  Common Stock. During the nine months ended March 31, 2018 months ended March 31, 2018 , we repurchased 300,000 shares at a cost of $27.9 million. Since the inception of our share repurchase programs and through March 31, 2018 , we have repurchased a total of 41.4 million shares at a cost of $1.6 billion. Shares that are repurchased are classified as treasury stock pending future use and reduce the number of shares outstanding used in calculating earnings per share. There is no expiration date for this program, and the program may be accelerated, suspended, delayed or discontinued at any time at the discretion of our board of directors. At March 31, 2018 , 13.3 million additional shares can be repurchased under the approved share repurchase program.  Preferred Stock. In April 1997, the board of directors designated 2.0 million shares of our $0.01 par value preferred stock as Series A Junior Participating Preferred Stock. No shares were issued or outstanding at March 31, 2018 and June 30, 2017 .  Stock Options and Restricted Stock Units. We have granted stock options and restricted stock units to personnel, including officers and directors, in accordance with the amended and restated ResMed Inc. 2009 Incentive Award Plan (as amended and restated, the “2009 Plan”). The options have expiration dates of seven years from the date of grant and the options and restricted stock units vest over one to four years.  At the annual meeting of our stockholders in November 2017, our stockholders approved an amendment and restatement to the 2009 Plan to increase the number of shares of common stock that may be issued or transferred pursuant to awards under the 2009 Plan by 7.4 million. While these additional shares have been authorized by the stockholders, they are pending registration with the SEC.  The amendment and restatement imposes a maximum award amount which may be granted under the 2009 Plan to non-employee director in a calendar year, which when taken together with any other cash fees earned for services as a non-employee director during the calendar year, has a total value of $0.7 million, or $1.2 million in the case of a non-employee director who is also serving as chairman of our board of directors. The amendment and restatement also increased the maximum amount payable pursuant to cash-denominated performance awards granted in any calendar year from $3.0 million to $5.0 million. In addition, the amendment and restatement extended the existing prohibition on the payment of dividends or dividend equivalents on unvested awards to apply to all awards, including time-based restricted stock, deferred stock and stock payment. The term of the 2009 Plan was extended by four years so that the plan expires on September 11, 2027 .  At March 31, 2018 , the maximum number of shares of our common stock authorized for issuance under the 2009 Plan was 51.1 million shares. The number of securities remaining available for future issuance under the 2009 Plan at March 31, 2018 was 17.9 million. The following table summarizes option activity during the nine months ended March 31, 2018 :   Options Weighted Average Exercise Price Weighted Average Remaining Contractual Term in Years  Outstanding at beginning of period 1,495,573 $ 47.09 3.9  Granted 238,815 84.98  Exercised (432,522) 34.92  Forfeited - -  Outstanding at end of period 1,301,866 $ 58.09 4.4  Exercise price of granted options $ 84.98  Options exercisable at end of period 787,339 $ 49.81  The following table summarizes the activity of restricted stock units during the nine months ended March 31, 2018 :   Restricted Stock Units Weighted Average Grant-Date Fair Value Weighted Average Remaining Contractual Term in Years  Outstanding at beginning of period 1,906,394 $ 53.26 1.6  Granted 472,158 80.08  Vested (652,065) 52.31  Expired (8,415) 57.40  Forfeited (58,483) 57.40  Outstanding at end of period 1,659,589 $ 62.72 1.9  Employee Stock Purchase Plan (the “ESPP”). Under the ESPP, we offer participants the right to purchase shares of our common stock at a discount during successive offering periods. During the nine months ended March 31, 2018 and March 31, 2017 , we issued 148,000 and 142,000 shares to our employees associated with the ESPP, respectively. At March 31, 2018 , the number of shares remaining available for future issuance under the ESPP is 0.7 million shares. |
Earnings Per Share
Earnings Per Share | 9 Months Ended |
Mar. 31, 2018 | |
Earnings Per Share [Abstract] | |
Earnings Per Share | (11) Earnings Per Share  Basic earnings per share is computed by dividing the net income available to common stockholders by the weighted average number of shares of common stock outstanding. For purposes of calculating diluted earnings per share, the denominator includes both the weighted average number of shares of common stock outstanding and the number of dilutive common stock equivalents such as stock options and restricted stock units.  Stock options and restricted stock units of 239,020 and 12,256 for the three months ended March 31, 2018 and March 31, 2017 , respectively, and stock options and restricted stock units of 125,995 and 415,038 for the nine months ended March 31, 2018 and March 31, 2017 , respectively, were not included in the computation of diluted earnings per share as the effect would have been anti-dilutive.  Basic and diluted earnings per share for the three and nine months ended March 31, 2018 and March 31, 2017 are calculated as follows (in thousands except per share data):   Three Months Ended March 31, Nine Months Ended March 31,  2018 2017 2018 2017  Numerator:  Net income $ 110,125 $ 87,823 $ 205,777 $ 240,672  Denominator:  Basic weighted-average common shares outstanding 142,898 141,714 142,688 141,266  Effect of dilutive securities:  Stock options and restricted stock units 1,087 1,010 1,207 1,097  Diluted weighted average shares 143,985 142,724 143,895 142,363  Basic earnings per share $ 0.77 $ 0.62 $ 1.44 $ 1.70  Diluted earnings per share $ 0.76 $ 0.62 $ 1.43 $ 1.69 |
Fair Value Measurements
Fair Value Measurements | 9 Months Ended |
Mar. 31, 2018 | |
Fair Value Measurements [Abstract] | |
Fair Value Measurements | (12) Fair Value Measurements  In determining the fair value measurements of our financial assets and liabilities, we consider the principal and most advantageous market in which we transact and consider assumptions that market participants would use when pricing the financial asset or liability. We maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value.  The hierarchies of inputs are as follows:     Level 1: Input prices quoted in an active market for identical financial assets or liabilities;   Level 2: Inputs other than prices quoted in Level 1, such as prices quoted for similar financial assets and liabilities in active markets, prices for identical assets and liabilities in markets that are not active or other inputs that are observable or can be corroborated by observable market data; and   Level 3 Input prices quoted that are significant to the fair value of the financial assets or liabilities which are not observable nor supported by an active market.  The following table summarizes our financial assets and liabilities at March 31, 2018 and June 30, 2017 , using the valuation input hierarchy (in thousands):   Level 1 Level 2 Level 3 Total  Balances at March 31, 2018  Foreign currency hedging instruments, net $ - $ (1,786) $ - $ (1,786)  Business acquisition contingent consideration $ - $ - $ (1,758) $ (1,758)  Balances at June 30, 2017  Foreign currency hedging instruments, net $ - $ 2,760 $ - $ 2,760  Business acquisition contingent consideration $ - $ - $ (1,580) $ (1,580)  We determine the fair value of our financial assets and liabilities as follows:  Foreign currency hedging instruments – These financial instruments are valued using third-party valuation models based on market observable inputs, including interest rate curves, on-market spot currency prices, volatilities and credit risk.  Contingent consideration – These liabilities include the fair value estimates of additional future payments that may be required for some of our previous business acquisitions based on the achievement of certain performance milestones. Each potential future payment is valued using the estimated probability of achieving each milestone, which is then discounted to present value.  The following is a reconciliation of changes in the fair value of contingent consideration for the nine months ended March 31, 2018 and March 31, 2017 (in thousands):   Nine Months Ended March 31,  2018 2017  Balance at the beginning of the period $ (1,580) $ (10,450)  Changes in fair value included in operating income (383) (10,076)  Payments 205 20,142  Foreign currency translation adjustments - 28  Balance at the end of the period $ (1,758) $ (356)  We did not have any significant non-financial assets or liabilities measured at fair value on March 31, 2018 or June 30, 2017 . |
Legal Actions And Contingencies
Legal Actions And Contingencies | 9 Months Ended |
Mar. 31, 2018 | |
Legal Actions And Contingencies [Abstract] | |
Legal Actions And Contingencies | (13) Legal Actions and Contingencies  Litigation In the normal course of business, we are subject to routine litigation incidental to our business. While the results of this litigation cannot be predicted with certainty, we believe that their final outcome will not, individually or in aggregate, have a material adverse effect on our consolidated financial statements taken as a whole.  Australian Taxation Office Audit  As described at note 7 – Income Taxes, we received Notices of Amended Assessments from the Australian Taxation Office (“ATO”) for the tax years 2009 to 2013 . Based on these assessments, the ATO is asserting that we owe $151.7 million in additional income tax and $38.4 million in accrued interest, of which $75.9 million was paid in April 2018 under a payment arrangement with the ATO. We do not agree with the ATO’s assessments and we continue to believe we are more likely than not to be successful in defending our position . H owever, if we are not successful, we will not receive a refund of the $75.9 million paid in April 2018 and we would be required to pay the remaining $75.9 million in additional income tax and $38.4 million in accrued interest. Additionally, we may be required to pay penalties that could be issued in relation to these assessments.  Contingent Obligations Under Recourse Provisions  We use independent leasing companies to offer financing to some of our customers for the purchase of some of our products. Under these arrangements, if the customer qualifies under the leasing company’s credit criteria and finances the transaction, the customers repay the leasing company on a fixed payment plan. For some of these arrangements, the customer’s receivable balance is with recourse, either limited or full, whereby we are responsible for repaying the leasing company should the customer default. We record the outstanding amount of receivables with full recourse in accrued expenses, which is offset by an equivalent amount recorded in accounts receivable. Additionally, we record a contingent provision for doubtful accounts for expected customer defaults based on historical default rates and any specific customer accounts with collection issues.  The following table summarizes the amount of receivables sold with recourse during the nine months ended March 31, 2018 and March 31, 2017 (in thousands):    Nine Months Ended March 31,  2018 2017  Total receivables sold:  Full recourse $ 16,125 $ 14,540  Limited recourse 56,302 52,976  Total $ 72,427 $ 67,516  The following table summarizes the maximum exposure on outstanding receivables sold with recourse and provision for doubtful accounts at March 31, 2018 and June 30, 2017 ( in thousands) :    March 31, 2018 June 30, 2017  Maximum exposure on outstanding receivables:  Full recourse $ 18,274 $ 18,068  Limited recourse 9,414 9,432  Total $ 27,688 $ 27,500   Provision for doubtful accounts - recourse receivables $ (1,062) $ (1,437) |
Derivative Instruments And Hedg
Derivative Instruments And Hedging Activities | 9 Months Ended |
Mar. 31, 2018 | |
Derivative Instruments And Hedging Activities [Abstract] | |
Derivative Instruments And Hedging Activities | (14) Derivative Instruments and Hedging Activities  We transact business in various foreign currencies, including a number of major European currencies as well as the Australian and Singapore dollars. We have significant foreign currency exposure through both our Australian and Singapore manufacturing activities, and international sales operations. We have established a foreign currency hedging program using purchased currency options and forward contracts to hedge foreign-currency-denominated financial assets, liabilities and manufacturing cash flows. The terms of such foreign currency hedging contracts generally do not exceed three years. The goal of this hedging program is to economically manage the financial impact of foreign currency exposures denominated mainly in Euros, and Australian and Singapore dollars. Under this program, increases or decreases in our foreign currency denominated financial assets, liabilities, and firm commitments are partially offset by gains and losses on the hedging instruments. We do not designate these foreign currency contracts as hedges. We have determined our hedge program to be a non-effective hedge as defined under the FASB-issued authoritative guidance. All movements in the fair value of the foreign currency instruments are recorded within other income, net in our condensed consolidated statements of income. We do not enter into financial instruments for trading or speculative purposes.  We held foreign currency instruments with notional amounts totaling $601.8 million and $ 568.2 million at March 31, 2018 and June 30, 2017 , respectively, to hedge foreign currency fluctuations. These contracts mature at various dates prior to December 31, 20 19 .  The following table summarizes the amount and location of our derivative financial instruments as of March 31, 2018 and June 30, 2017 (in thousands):   March 31, 2018 June 30, 2017 Balance Sheet Caption  Foreign currency hedging instruments $ 980 $ 2,614 Other assets - current  Foreign currency hedging instruments - 1,273 Other assets - non current  Foreign currency hedging instruments (2,766) (1,127) Accrued expenses  $ (1,786) $ 2,760  The following table summarizes the amount and location of gains (losses) associated with our derivative financial instruments for the nine months ended March 31, 2018 and March 31, 2017 , respectively (in thousands):   Gain /(Loss) Recognized Income Statement Caption  Nine Months Ended March 31,  2018 2017  Foreign currency hedging instruments $ (10,013) $ 1,812 Other, net  Other foreign-currency-denominated transactions 7,308 3,622 Other, net  $ (2,705) $ 5,434  We are exposed to credit-related losses in the event of non-performance by counter parties to financial instruments. We minimize counterparty credit risk by entering into derivative transactions with major financial institutions and we do not expect material losses as a result of default by our counterparties. |
Restructuring Expenses
Restructuring Expenses | 9 Months Ended |
Mar. 31, 2018 | |
Restructuring Expenses [Abstract] | |
Restructuring Expenses | ( 15 ) Restructuring Expenses  During the three and nine months ended March 31, 2018 we recognized restructuring expenses of $10.9 million associated with a global strategic workforce planning review, which resulted in a reduction in headcount across most of our functions and locations. Employee-related payments represented $10.2 million of the total expense incurred, with the remaining expense relating to legal and consulting services associated with the completion of the employee severances . As of March 31, 2018, an outstanding, unpaid balance of $3.0 million had been recorded as a liability in accrued expenses. The restructuring activity was partially completed by March 31, 2018 and we expect the remaining activity to be completed during the quarter ending June 30, 2018. Associated with this activity, w e expect to record additional restructuring expenses of approximately $7.0 million during the quarter ending June 30, 2018, which will include employee-related severance paymen ts and site closure costs.  During the three months ended March 31, 2017 we recognized restructuring expenses of $7.9 million associated with the closure of our Paris manufacturing activities. The restructure cost consisted primarily of severance payments to employees and site closure costs. The restructure was substantially completed by March 31, 2017.  During the nine months ended March 31, 2017 we recognized restructuring expenses of $12.4 million associated with the closure of our Paris manufacturing activities and reorganization of our global research and development activities. The restructure expenses consisted primarily of severance payments to employees, site closure costs and associated project cancellation costs. |
Subsequent Event
Subsequent Event | 9 Months Ended |
Mar. 31, 2018 | |
Subsequent Event [Abstract] | |
Subsequent Event | ( 16 ) Subsequent Event  Debt Refinancing  On April 17, 2018, we entered into an Amended and Restated Credit Agreement (the “Revolving Credit Agreement”) as borrower, with lenders MUFG Union Bank, N.A., as administrative agent, joint lead arranger, joint book runner, swing line lender and letter of credit issuer, and Westpac Banking Corporation, as syndication agent, joint lead arranger and joint book runner. The Revolving Credit Agreement, among other things, provides a senior unsecured revolving credit facility of $800 million, with an uncommitted option to increase the revolving credit facility by an additional $300 million.  Additionally, on April 17, 2018, ResMed Limited entered into a Syndicated Facility Agreement (the “Term Credit Agreement”) as borrower, with lenders MUFG Union Bank, N.A., as administrative agent, joint lead arranger and joint book runner, and Westpac Banking Corporation, as syndication agent, joint lead arranger and joint book runner. The Term Credit Agreement, among other things, provides ResMed Limited a senior unsecured term credit facility of $200 million.  The Revolving Credit Agreement and Term Credit Agreement each terminate on April 17, 2023 , when all unpaid principal and interest under the loans must be repaid. The term credit facility will also amortize on a semi-annual basis, with a $6 million principal payment required on each such semi-annual amortization date. The outstanding principal amounts will bear interest at a rate equal to LIBOR plus 0.75% to 1.50% (depending on the then-applicable leverage ratio) or the Base Rate (as defined in the Revolving Credit Agreement and the Term Credit Agreement, as applicable) plus 0.0% to 0.50% (depending on the then-applicable leverage ratio). An applicable commitment fee of 0.100% to 0.175% (depending on the then-applicable leverage ratio) applies on the unused portion of the revolving credit facility.  Our obligations under the Revolving Credit Agreement and Term Credit Agreement are guaranteed by us and certain of our direct and indirect U.S. subsidiaries, including, in each case, ResMed Corp., ResMed Motor Technologies Inc., Birdie Inc., Inova Labs, Inc., Brightree LLC, Brightree Services LLC, Brightree Home Health & Hospice LLC, and Brightree Patient Collections LLC. The Revolving Credit Agreement and Term Credit Agreement contain customary covenants, including, in each case, a financial covenant that requires that we maintain a maximum leverage ratio of funded debt to EBITDA (as defined in the Revolving Credit Agreement and Term Credit Agreement, as applicable). The entire principal amounts of the revolving credit facility and term credit facility, and, in each case, any accrued but unpaid interest may be declared immediately due and payable if an event of default occurs, as defined in the Revolving Credit Agreement and the Term Credit Agreement, as applicable. Events of default under the Revolving Credit Agreement and the Term Credit Agreement include, in each case, failure to make payments when due, the occurrence of a default in the performance of any covenants in the respective agreements or related documents, or certain changes of control of ResMed, the respective guarantors of the revolving credit facility and the term credit facility, ResMed Holdings Ltd and/or ResMed EAP Holdings LLC. |
Summary Of Significant Accoun23
Summary Of Significant Accounting Policies (Policy) | 9 Months Ended |
Mar. 31, 2018 | |
Summary Of Significant Accounting Policies [Abstract] | |
Organization And Basis Of Presentation | Organization and Basis of Presentation  ResMed Inc. (referred to herein as “we”, “us”, “our” or the “Company”) is a Delaware corporation formed in March 1994 as a holding company for the ResMed Group. Through our subsidiaries, we design, manufacture and market equipment for the diagnosis and treatment of sleep-disordered breathing and other respiratory disorders, including obstructive sleep apnea. Our manufacturing operations are located in Australia, Singapore, Malaysia, France, China and the United States. Major distribution and sales sites are located in the United States, Germany, France, the United Kingdom, Switzerland, Australia, Japan, China, Norway and Sweden.  The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (“U.S. GAAP”) for interim financial information and with the instructions to Form 10-Q and the rules of the U.S. Securities and Exchange Commission (“SEC”). Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. In the opinion of management, all necessary adjustments, which consisted only of normal recurring items, have been included in the accompanying financial statements to present fairly the results of the interim periods. The results of operations for the interim periods presented are not necessarily indicative of the results that may be expected for the year ending June 30, 2018 .  The condensed consolidated financial statements for the three and nine months ended March 31, 2018 and March 31, 2017 are unaudited and should be read in conjunction with the consolidated financial statements and notes thereto included in our Form 10-K for the year ended June 30, 2017 . |
Revenue Recognition | Revenue Recognition  We generally record revenue on product sales at the time of shipment, which is when title transfers to the customer. We do not record revenue on product sales which require customer acceptance until we receive acceptance. We initially defer service revenue received in advance from service contracts and recognize that deferred revenue ratably over the life of the service contract. We initially defer revenue we receive in advance from rental unit contracts and recognize that deferred revenue ratably over the life of the rental contract. Otherwise, we recognize revenue from rental unit contracts ratably over the life of the rental contract. We include in revenue freight charges we bill to customers. We charge all freight-related expenses to cost of sales. Taxes assessed by government authorities that are imposed on and concurrent with revenue-producing transactions, such as sales and value added taxes, are excluded from revenue.  We do not recognize revenues to the extent that we offer a right of return or other recourse with respect to the sale of our products, other than returns for product defects or other warranty claims, nor do we recognize revenues if we offer variable sale prices for subsequent events or activities. However, as part of our sales processes, we may provide upfront discounts for large orders, one-time special pricing to support new product introductions, sales rebates for centralized purchasing entities or price-breaks for regular order volumes. We record the costs of all such programs as an adjustment to revenue at the time the related revenue is recognized. Our products are predominantly therapy-based equipment and require no installation. Therefore, we have no installation obligations. For multiple-element arrangements, we allocate arrangement consideration to the deliverables by use of the relative selling price method. The selling price used for each deliverable is based on vendor–specific objective evidence.  We also generate revenue from time-based licensing of our software and associated services. In most instances, revenue is generated under sales agreements with multiple elements comprising subscription fees and professional services, which typically have contract terms of one to three years. We evaluate each element in these multiple-element arrangements to determine whether they represent a separate unit of accounting and recognize each element as the services are performed. |
Provision For Warranty | Provision for Warranty  We provide for the estimated cost of product warranties at the time the related revenue is recognized. We determine the amount of this provision by using a financial model, which takes into consideration actual historical expenses and potential risks associated with our different products. We use this financial model to calculate the future probable expenses related to warranty and the required level of the warranty provision. Although we engage in product improvement programs and processes, our warranty obligation is affected by product failure rates and costs incurred to correct those product failures. Should actual product failure rates or estimated costs to repair those product failures differ from our estimates, we would be required to revise our estimated warranty provision. |
New Accounting Pronouncements | New Accounting Pronouncements  (a) Recently issued accounting standards not yet adopted  ASU No. 2014-09, “Revenue from Contracts with Customers” In May, 2014, the Financial Accounting Standards Board (the “FASB”) issued Accounting Standards Update (“ASU”), ASU No. 2014-09, “Revenue from Contracts with Customers” (Topic 606), which requires an entity to recognize the amount of revenue to which it expects to be entitled for the transfer of promised goods or services to customers. Since its initial release, the FASB has issued several amendments to the standard, which include clarification of accounting guidance related to identification of performance obligations, intellectual property licenses, and principal vs. agent considerations. ASU 2014-09 and all subsequent amendments (collectively, the “new revenue recognition standards”) will replace most existing revenue recognition guidance in U.S. GAAP when it becomes effective. The guidance also requires improved disclosures on the nature, amount, timing, and uncertainty of revenue that is recognized.  We formed an implementation team in fiscal year June 30, 2017 to oversee adoption of the new revenue recognition standards. The implementation team completed the diagnostic phase of its project which has included assessing the composition and detailed review of our contract portfolio and selection of sample contracts for assessment. There are a number of steps in the team’s project plan that remain to be completed including: finalizing contract reviews, evaluating the impact, and working through required changes to systems, business processes and controls to support the adoption of the new revenue recognition standards. We expect there will be changes to our accounting policies to align with terminology and concepts in the new revenue recognition standards as well as increased disclosures relating to our revenue streams, contract-related balances and contract details.  The new revenue recognition standard is effective for us beginning in the first quarter of the fiscal year ending June 30, 2019 and early application is permitted for annual or interim periods beginning after December 15, 2016. The new guidance can be applied retrospectively to each prior reporting period presented, or retrospectively with the cumulative effect of the change recognized at the date of the initial application. Assuming the impact is not material, we expect to adopt the new revenue recognition standards using the modified retrospective method with an adjustment to beginning retained earnings for the cumulative effect of the change.  ASU No. 2016-01, "Financial Instruments - Overall" In January 2016, the FASB issued Accounting Standards Update ASU No. 2016-01, "Financial Instruments - Overall" (Topic 825-10). The amendments address certain aspects of recognition, measurement, presentation, and disclosure of financial instruments, and require equity securities to be measured at fair value with changes in fair value recognized through net income. The amendments also simplify the impairment assessment of equity investments without readily determinable fair values by requiring a qualitative assessment for impairment quarterly at each reporting period. The amendments in ASU 2016-01 will be effective for our first quarter of the fiscal year ending June 30, 2019. An entity should apply the amendments by means of a cumulative-effect adjustment to the balance sheet as of the beginning of the fiscal year of adoption, with prospective adoption of the amendments related to equity securities without readily determinable fair values existing as of the date of adoption. We are currently assessing the impact as this standard will be relevant for our Cost-Method Investments.  ASU No. 2016-02, “Leases” In February 2016, the FASB issued Accounting Standard Update ASU No. 2016-02, “Leases” (Topic 842). Under the new guidance , lessees are required to recognize a right-of-use asset and a lease liability on the balance sheet for all leases, other than those that meet the definition of a short-term lease. This update will establish a lease asset and lease liability by lessees for those leases classified as operating under current GAAP. Leases will be classified as either operating or finance under the new guidance. Operating leases will result in straight-line expense in the income statement, similar to current operating leases, and finance leases will result in more expense being recognized in the earlier years of the lease term, similar to current capital leases. For lessors, the update will more closely align lease accounting to comparable guidance in the new revenue standards described.  The new standard is effective for us beginning in the first quarter of the fiscal year ending June 30, 2020 and early application is permitted. ASU 2016-02 will be adopted on a modified retrospective transition basis for leases existing at, or entered into after, the beginning of the earliest comparative period presented in the financial statements. We are currently evaluating the impact of this standard on our consolidated financial statements and expect to commence an implementation project during the fiscal year ending June 30, 2018. While the formal impact assessment has not commenced, we expect this amendment will affect the way we account for operating leases where we are the lessee (as described above), require reassessment of how we account for revenue where we are the lessor and will result in increased disclosures for all lease arrangements.  ASU No. 2016-16, “Income Taxes: Intra-Entity Transfers of Assets Other Than Inventory” In October 2016, the FASB issued Accounting Standard Update ASU No. 2016-16, “Income Taxes: Intra-Entity Transfers of Assets Other Than Inventory” (Topic 740). Under the new guidance, an entity is required to recognize the income tax consequences of an intra-entity transfer of an asset other than inventory when the transfer occurs and eliminates the exception for an intra-entity transfer of an asset other than inventory. ASU 2016-16 will be effective for the first quarter of our fiscal year ending June 30, 2019 and is required to be adopted on a modified retrospective basis, with a cumulative-effect adjustment recorded directly to retained earnings for intra-entity transfers that occur before the adoption date. Based on this adoption method , we expect to record a cumulative-effect adjustment directly to retained earnings and a reduction in prepaid taxes of approximately $60.0 million on July 1, 2018.  (b) Recently adopted accounting pronouncements  We have not adopted any new accounting pronouncements during the nine months ended March 31, 2018 . |
Inventories (Tables)
Inventories (Tables) | 9 Months Ended |
Mar. 31, 2018 | |
Inventories [Abstract] | |
Schedule Of Inventories |   March 31, 2018 June 30, 2017  Raw materials $ 86,692 $ 75,658  Work in progress 3,787 4,297  Finished goods 198,224 188,364  Total inventories $ 288,703 $ 268,319  |
Property, Plant And Equipment (
Property, Plant And Equipment (Tables) | 9 Months Ended |
Mar. 31, 2018 | |
Property, Plant And Equipment [Abstract] | |
Components Of Property, Plant And Equipment |   March 31, 2018 June 30, 2017  Machinery and equipment $ 245,339 $ 230,632  Computer equipment 164,969 154,032  Furniture and fixtures 52,180 47,074  Vehicles 7,904 7,667  Clinical, demonstration and rental equipment 97,594 86,024  Leasehold improvements 39,240 35,932  Land 55,317 55,311  Buildings 233,978 233,868  896,521 850,540  Accumulated depreciation and amortization (498,540) (456,299)  Property, plant and equipment, net $ 397,981 $ 394,241  |
Goodwill (Tables)
Goodwill (Tables) | 9 Months Ended |
Mar. 31, 2018 | |
Goodwill And Other Intangible Assets [Abstract] | |
Schedule Of Changes In Carrying Amount Of Goodwill |   Nine Months Ended March 31,  2018 2017  Balance at the beginning of the period $ 1,064,874 $ 1,059,245  Business acquisition 247 (2,436)  Foreign currency translation adjustments 15,827 (6,726)  Balance at the end of the period $ 1,080,948 $ 1,050,083  |
Other Intangible Assets (Tables
Other Intangible Assets (Tables) | 9 Months Ended |
Mar. 31, 2018 | |
Goodwill And Other Intangible Assets [Abstract] | |
Schedule Of Other Intangible Assets |   March 31, 2018 June 30, 2017  Developed/core product technology $ 208,134 $ 206,258  Accumulated amortization (111,277) (93,079)  Developed/core product technology, net 96,857 113,179  Trade names 48,969 48,768  Accumulated amortization (15,515) (10,894)  Trade names, net 33,454 37,874  Non-compete agreements 3,698 3,660  Accumulated amortization (2,576) (2,236)  Non-compete agreements, net 1,122 1,424  Customer relationships 124,552 122,458  Accumulated amortization (51,036) (40,050)  Customer relationships, net 73,516 82,408  In-process research and development - 4,100  Accumulated amortization - -  In-process research and development, net - 4,100  Patents 93,139 85,780  Accumulated amortization (69,865) (62,965)  Patents, net 23,274 22,815  Total other intangibles, net $ 228,223 $ 261,800  |
Cost-Method Investments (Tables
Cost-Method Investments (Tables) | 9 Months Ended |
Mar. 31, 2018 | |
Cost-Method Investments [Abstract] | |
Schedule Of Reconciliation Of Changes In Cost-Method Investments |   Nine Months Ended March 31,  2018 2017  Balance at the beginning of the period $ 38,324 $ 33,815  Investments 6,445 6,464  Impairment of cost-method investments (3,620) (588)  Balance at the end of the period $ 41,149 $ 39,691  |
Product Warranties (Tables)
Product Warranties (Tables) | 9 Months Ended |
Mar. 31, 2018 | |
Product Warranties [Abstract] | |
Schedule Of Changes In Liability For Warranty Costs |   Nine Months Ended March 31,  2018 2017  Balance at the beginning of the period $ 19,558 $ 15,043  Warranty accruals for the period 13,041 15,237  Warranty costs incurred for the period (13,135) (10,085)  Foreign currency translation adjustments 485 (8)  Balance at the end of the period $ 19,949 $ 20,187  |
Debt (Tables)
Debt (Tables) | 9 Months Ended |
Mar. 31, 2018 | |
Debt [Abstract] | |
Schedule Of Debt |   March 31, 2018 June 30, 2017  Long-term debt $ 810,000 $ 1,080,000  Deferred borrowing costs - (1,389)  Long-term debt, net $ 810,000 $ 1,078,611  Total debt $ 810,000 $ 1,078,611  |
Stockholders' Equity (Tables)
Stockholders' Equity (Tables) | 9 Months Ended |
Mar. 31, 2018 | |
Stockholders' Equity [Abstract] | |
Schedule Of Option Activity |   Options Weighted Average Exercise Price Weighted Average Remaining Contractual Term in Years  Outstanding at beginning of period 1,495,573 $ 47.09 3.9  Granted 238,815 84.98  Exercised (432,522) 34.92  Forfeited - -  Outstanding at end of period 1,301,866 $ 58.09 4.4  Exercise price of granted options $ 84.98  Options exercisable at end of period 787,339 $ 49.81  |
Schedule Of Activity Of Restricted Stock Units |   Restricted Stock Units Weighted Average Grant-Date Fair Value Weighted Average Remaining Contractual Term in Years  Outstanding at beginning of period 1,906,394 $ 53.26 1.6  Granted 472,158 80.08  Vested (652,065) 52.31  Expired (8,415) 57.40  Forfeited (58,483) 57.40  Outstanding at end of period 1,659,589 $ 62.72 1.9  |
Earnings Per Share (Tables)
Earnings Per Share (Tables) | 9 Months Ended |
Mar. 31, 2018 | |
Earnings Per Share [Abstract] | |
Schedule Of Basic And Diluted Earnings Per Share |   Three Months Ended March 31, Nine Months Ended March 31,  2018 2017 2018 2017  Numerator:  Net income $ 110,125 $ 87,823 $ 205,777 $ 240,672  Denominator:  Basic weighted-average common shares outstanding 142,898 141,714 142,688 141,266  Effect of dilutive securities:  Stock options and restricted stock units 1,087 1,010 1,207 1,097  Diluted weighted average shares 143,985 142,724 143,895 142,363  Basic earnings per share $ 0.77 $ 0.62 $ 1.44 $ 1.70  Diluted earnings per share $ 0.76 $ 0.62 $ 1.43 $ 1.69  |
Fair Value Measurements (Tables
Fair Value Measurements (Tables) | 9 Months Ended |
Mar. 31, 2018 | |
Fair Value Measurements [Abstract] | |
Summary Of Financial Assets And Liabilities |   Level 1 Level 2 Level 3 Total  Balances at March 31, 2018  Foreign currency hedging instruments, net $ - $ (1,786) $ - $ (1,786)  Business acquisition contingent consideration $ - $ - $ (1,758) $ (1,758)  Balances at June 30, 2017  Foreign currency hedging instruments, net $ - $ 2,760 $ - $ 2,760  Business acquisition contingent consideration $ - $ - $ (1,580) $ (1,580)  |
Reconciliation For Fair Value Measurements Using Significant Unobservable Inputs |   Nine Months Ended March 31,  2018 2017  Balance at the beginning of the period $ (1,580) $ (10,450)  Changes in fair value included in operating income (383) (10,076)  Payments 205 20,142  Foreign currency translation adjustments - 28  Balance at the end of the period $ (1,758) $ (356)  |
Legal Actions And Contingenci34
Legal Actions And Contingencies (Tables) | 9 Months Ended |
Mar. 31, 2018 | |
Legal Actions And Contingencies [Abstract] | |
Summary Of Receivables Sold With Recourse |   Nine Months Ended March 31,  2018 2017  Total receivables sold:  Full recourse $ 16,125 $ 14,540  Limited recourse 56,302 52,976  Total $ 72,427 $ 67,516  |
Summary Of Maximum Exposure On Outstanding Receivables Sold With Recourse And Provision |   March 31, 2018 June 30, 2017  Maximum exposure on outstanding receivables:  Full recourse $ 18,274 $ 18,068  Limited recourse 9,414 9,432  Total $ 27,688 $ 27,500   Provision for doubtful accounts - recourse receivables $ (1,062) $ (1,437)  |
Derivative Instruments And He35
Derivative Instruments And Hedging Activities (Tables) | 9 Months Ended |
Mar. 31, 2018 | |
Derivative Instruments And Hedging Activities [Abstract] | |
Summary Of Amount And Location Of Derivative Financial Instruments |   March 31, 2018 June 30, 2017 Balance Sheet Caption  Foreign currency hedging instruments $ 980 $ 2,614 Other assets - current  Foreign currency hedging instruments - 1,273 Other assets - non current  Foreign currency hedging instruments (2,766) (1,127) Accrued expenses  $ (1,786) $ 2,760  |
Summary Of Gains (Losses) Associated With Derivative Financial Instruments |   Gain /(Loss) Recognized Income Statement Caption  Nine Months Ended March 31,  2018 2017  Foreign currency hedging instruments $ (10,013) $ 1,812 Other, net  Other foreign-currency-denominated transactions 7,308 3,622 Other, net  $ (2,705) $ 5,434  |
Summary Of Significant Accoun36
Summary Of Significant Accounting Policies (Narrative) (Details) - USD ($) $ in Millions | 9 Months Ended | |
Mar. 31, 2018 | Jul. 01, 2018 | |
Scenario, Forecast [Member] | Accounting Standards Update 2016-16 [Member] | ||
Summary Of Significant Accounting Policies [Line Items] | ||
Cumulative effect adjustment to retained earnings and reduction prepaid taxes | $ 60 | |
Minimum [Member] | ||
Summary Of Significant Accounting Policies [Line Items] | ||
Contract term under revenue recognition | 1 year | |
Maximum [Member] | ||
Summary Of Significant Accounting Policies [Line Items] | ||
Contract term under revenue recognition | 3 years |
Inventories (Schedule Of Invent
Inventories (Schedule Of Inventories) (Details) - USD ($) $ in Thousands | Mar. 31, 2018 | Jun. 30, 2017 |
Inventories [Abstract] | ||
Raw materials | $ 86,692 | $ 75,658 |
Work in progress | 3,787 | 4,297 |
Finished goods | 198,224 | 188,364 |
Total inventories | $ 288,703 | $ 268,319 |
Property, Plant And Equipment38
Property, Plant And Equipment (Components Of Property, Plant And Equipment) (Details) - USD ($) $ in Thousands | Mar. 31, 2018 | Jun. 30, 2017 |
Property, Plant and Equipment [Line Items] | ||
Property, plant and equipment, gross | $ 896,521 | $ 850,540 |
Accumulated depreciation and amortization | (498,540) | (456,299) |
Property, plant and equipment, net | 397,981 | 394,241 |
Machinery And Equipment [Member] | ||
Property, Plant and Equipment [Line Items] | ||
Property, plant and equipment, gross | 245,339 | 230,632 |
Computer Equipment [Member] | ||
Property, Plant and Equipment [Line Items] | ||
Property, plant and equipment, gross | 164,969 | 154,032 |
Furniture And Fixtures [Member] | ||
Property, Plant and Equipment [Line Items] | ||
Property, plant and equipment, gross | 52,180 | 47,074 |
Vehicles [Member] | ||
Property, Plant and Equipment [Line Items] | ||
Property, plant and equipment, gross | 7,904 | 7,667 |
Clinical, Demonstration And Rental Equipment [Member] | ||
Property, Plant and Equipment [Line Items] | ||
Property, plant and equipment, gross | 97,594 | 86,024 |
Leasehold Improvements [Member] | ||
Property, Plant and Equipment [Line Items] | ||
Property, plant and equipment, gross | 39,240 | 35,932 |
Land [Member] | ||
Property, Plant and Equipment [Line Items] | ||
Property, plant and equipment, gross | 55,317 | 55,311 |
Buildings [Member] | ||
Property, Plant and Equipment [Line Items] | ||
Property, plant and equipment, gross | $ 233,978 | $ 233,868 |
Goodwill (Schedule Of Changes I
Goodwill (Schedule Of Changes In Carrying Amount Of Goodwill) (Details) - USD ($) $ in Thousands | 9 Months Ended | |
Mar. 31, 2018 | Mar. 31, 2017 | |
Goodwill And Other Intangible Assets [Abstract] | ||
Balance at the beginning of the period | $ 1,064,874 | $ 1,059,245 |
Business acquisition | 247 | (2,436) |
Foreign currency translation adjustments | 15,827 | (6,726) |
Balance at the end of the period | $ 1,080,948 | $ 1,050,083 |
Other Intangible Assets (Schedu
Other Intangible Assets (Schedule Of Other Intangible Assets) (Details) - USD ($) $ in Thousands | 9 Months Ended | |
Mar. 31, 2018 | Jun. 30, 2017 | |
Finite-Lived Intangible Assets [Line Items] | ||
Total other intangibles, net | $ 228,223 | $ 261,800 |
Developed/Core Product Technology [Member] | ||
Finite-Lived Intangible Assets [Line Items] | ||
Other intangibles, gross | 208,134 | 206,258 |
Accumulated amortization | (111,277) | (93,079) |
Total other intangibles, net | 96,857 | 113,179 |
Trade Names [Member] | ||
Finite-Lived Intangible Assets [Line Items] | ||
Other intangibles, gross | 48,969 | 48,768 |
Accumulated amortization | (15,515) | (10,894) |
Total other intangibles, net | 33,454 | 37,874 |
Non-Compete Agreements [Member] | ||
Finite-Lived Intangible Assets [Line Items] | ||
Other intangibles, gross | 3,698 | 3,660 |
Accumulated amortization | (2,576) | (2,236) |
Total other intangibles, net | 1,122 | 1,424 |
Customer Relationships [Member] | ||
Finite-Lived Intangible Assets [Line Items] | ||
Other intangibles, gross | 124,552 | 122,458 |
Accumulated amortization | (51,036) | (40,050) |
Total other intangibles, net | 73,516 | 82,408 |
In-Process Research And Development [Member] | ||
Finite-Lived Intangible Assets [Line Items] | ||
Other intangibles, gross | 4,100 | |
Total other intangibles, net | 4,100 | |
Patents [Member] | ||
Finite-Lived Intangible Assets [Line Items] | ||
Other intangibles, gross | 93,139 | 85,780 |
Accumulated amortization | (69,865) | (62,965) |
Total other intangibles, net | $ 23,274 | $ 22,815 |
Minimum [Member] | ||
Finite-Lived Intangible Assets [Line Items] | ||
Intangible assets, estimated useful life | 2 years | |
Maximum [Member] | ||
Finite-Lived Intangible Assets [Line Items] | ||
Intangible assets, estimated useful life | 15 years |
Cost-Method Investments (Narrat
Cost-Method Investments (Narrative) (Details) - USD ($) $ in Thousands | 9 Months Ended | |||
Mar. 31, 2018 | Mar. 31, 2017 | Jun. 30, 2017 | Jun. 30, 2016 | |
Cost-Method Investments [Abstract] | ||||
Aggregate carrying amount of cost-method investments | $ 41,149 | $ 39,691 | $ 38,324 | $ 33,815 |
Impairment losses related to cost-method investments | $ 3,620 | $ 588 |
Cost-Method Investments (Schedu
Cost-Method Investments (Schedule Of Reconciliation Of Changes In Cost-Method Investments) (Details) - USD ($) $ in Thousands | 9 Months Ended | |
Mar. 31, 2018 | Mar. 31, 2017 | |
Cost-Method Investments [Abstract] | ||
Balance at the beginning of the period | $ 38,324 | $ 33,815 |
Investments | 6,445 | 6,464 |
Impairment of cost-method investments | (3,620) | (588) |
Balance at the end of the period | $ 41,149 | $ 39,691 |
Income Taxes (Narrative) (Detai
Income Taxes (Narrative) (Details) - USD ($) $ in Thousands | 1 Months Ended | 3 Months Ended | 9 Months Ended | |||
Mar. 31, 2018 | Mar. 31, 2018 | Mar. 31, 2017 | Mar. 31, 2018 | Mar. 31, 2017 | Jun. 30, 2017 | |
Income Taxes [Line Items] | ||||||
Income taxes payable | $ 124,569 | $ 124,569 | $ 124,569 | $ 29,150 | ||
Income tax expense (benefit) | 20,018 | $ 20,167 | 174,617 | $ 56,449 | ||
Tax Year 2018 [Member] | Scenario, Plan [Member] | ||||||
Income Taxes [Line Items] | ||||||
Income tax expense (benefit) | 132,200 | |||||
Additional income tax expense from transition tax imposed on accumulated foreign earnings | 5,600 | 125,500 | ||||
Additional income tax expense from adjustment of deferred tax assets | 6,700 | |||||
Australian Taxation Office [Member] | ||||||
Income Taxes [Line Items] | ||||||
Additional tax liabilities related to assessments | 151,700 | |||||
Interest related to assessments | 38,400 | 38,400 | 38,400 | |||
Australian Taxation Office [Member] | Due April 2018 [Member] | ||||||
Income Taxes [Line Items] | ||||||
Income taxes payable | $ 75,900 | $ 75,900 | $ 75,900 | |||
Australian Taxation Office [Member] | Minimum [Member] | ||||||
Income Taxes [Line Items] | ||||||
Tax year under audit | 2,009 | |||||
Australian Taxation Office [Member] | Maximum [Member] | ||||||
Income Taxes [Line Items] | ||||||
Tax year under audit | 2,013 |
Product Warranties (Schedule Of
Product Warranties (Schedule Of Changes In Liability For Warranty Costs) (Details) - USD ($) $ in Thousands | 9 Months Ended | |
Mar. 31, 2018 | Mar. 31, 2017 | |
Product Warranties [Abstract] | ||
Balance at the beginning of the period | $ 19,558 | $ 15,043 |
Warranty accruals for the period | 13,041 | 15,237 |
Warranty costs incurred for the period | (13,135) | (10,085) |
Foreign currency translation adjustments | 485 | (8) |
Balance at the end of the period | $ 19,949 | $ 20,187 |
Debt (Narrative) (Details)
Debt (Narrative) (Details) - USD ($) $ in Thousands | Jan. 09, 2017 | Apr. 04, 2016 | Oct. 31, 2013 | Mar. 31, 2018 | Jun. 30, 2017 | Jan. 08, 2017 | Apr. 03, 2016 |
Debt Instrument [Line Items] | |||||||
Outstanding under the revolving credit facility | $ 810,000 | $ 1,078,611 | |||||
Union Bank, N.A. and HSBC Bank USA [Member] | Revolving Credit Facility [Member] | |||||||
Debt Instrument [Line Items] | |||||||
Maximum borrowing capacity | $ 1,300,000 | $ 700,000 | $ 1,000,000 | $ 700,000 | |||
Uncommitted option to increase credit facility | $ 300,000 | $ 300,000 | |||||
Credit facility termination date | Oct. 31, 2018 | ||||||
Interest rate on outstanding principal amount | 3.00% | ||||||
Union Bank, N.A. and HSBC Bank USA [Member] | Letters Of Credit [Member] | |||||||
Debt Instrument [Line Items] | |||||||
Maximum borrowing capacity | $ 25,000 | ||||||
Minimum [Member] | Union Bank, N.A. and HSBC Bank USA [Member] | |||||||
Debt Instrument [Line Items] | |||||||
Commitment fees percentage rate on unused portion of credit facility | 0.15% | ||||||
Minimum [Member] | Union Bank, N.A. and HSBC Bank USA [Member] | London Interbank Offered Rate (LIBOR) [Member] | |||||||
Debt Instrument [Line Items] | |||||||
Credit facility interest rate equal to reference rate plus | 1.00% | ||||||
Maximum [Member] | Union Bank, N.A. and HSBC Bank USA [Member] | |||||||
Debt Instrument [Line Items] | |||||||
Commitment fees percentage rate on unused portion of credit facility | 0.25% | ||||||
Maximum [Member] | Union Bank, N.A. and HSBC Bank USA [Member] | London Interbank Offered Rate (LIBOR) [Member] | |||||||
Debt Instrument [Line Items] | |||||||
Credit facility interest rate equal to reference rate plus | 2.00% | ||||||
Brightree LLC [Member] | Union Bank, N.A. and HSBC Bank USA [Member] | Revolving Credit Facility [Member] | |||||||
Debt Instrument [Line Items] | |||||||
Maximum borrowing capacity | $ 1,000,000 | ||||||
Uncommitted option to increase credit facility | $ 300,000 |
Debt (Schedule Of Debt) (Detail
Debt (Schedule Of Debt) (Details) - USD ($) $ in Thousands | Mar. 31, 2018 | Jun. 30, 2017 |
Debt [Abstract] | ||
Long-term debt | $ 810,000 | $ 1,080,000 |
Deferred borrowing costs | (1,389) | |
Long-term debt, net | 810,000 | 1,078,611 |
Total debt | $ 810,000 | $ 1,078,611 |
Stockholders' Equity (Narrative
Stockholders' Equity (Narrative) (Details) - USD ($) $ / shares in Units, $ in Thousands | 1 Months Ended | 9 Months Ended | ||||
Dec. 31, 2017 | Nov. 30, 2017 | Mar. 31, 2018 | Mar. 31, 2017 | Jun. 30, 2017 | Apr. 30, 1997 | |
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||||
Common shares repurchased under repurchase program | 300,000 | |||||
Cost of common shares repurchased | $ 27,900 | |||||
Total number of shares repurchased pursuant to the repurchase program | 41,386,234 | 41,086,234 | ||||
Total cost of shares repurchased pursuant to the repurchase program | $ 1,574,508 | $ 1,546,611 | ||||
Additional shares that can be repurchased under the approved share repurchase program | 13,300,000 | |||||
Preferred stock, shares authorized | 2,000,000 | 2,000,000 | ||||
Preferred stock at par value | $ 0.01 | $ 0.01 | ||||
Preferred stock, shares issued | 0 | 0 | ||||
Series A Junior Participating Preferred Stock [Member] | ||||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||||
Preferred stock, shares authorized | 2,000,000 | |||||
Preferred stock at par value | $ 0.01 | |||||
Preferred stock, shares issued | 0 | 0 | ||||
Preferred stock, shares outstanding | 0 | 0 | ||||
2009 Plan [Member] | ||||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||||
Expiration period | 7 years | |||||
Maximum amount payable pursant to cash denominated performance awards granted | $ 5,000 | $ 3,000 | ||||
Vesting period | 4 years | |||||
Expiration date | Sep. 11, 2027 | |||||
Common stock authorized for issuance | 51,100,000 | |||||
Common stock authorized for issuance and pending registration | 7,400,000 | |||||
Number of securities remaining available for future issuance | 17,900,000 | |||||
2009 Plan [Member] | Non Employee Director [Member] | ||||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||||
Maximum award amount with other cash fees earned for services | $ 700 | |||||
2009 Plan [Member] | Board Of Directors Chairman [Member] | ||||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||||
Maximum award amount with other cash fees earned for services | $ 1,200 | |||||
Employee Stock Purchase Plan [Member] | ||||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||||
Number of securities remaining available for future issuance | 700,000 | |||||
Shares issued under Employee Stock Purchase Plan | 148,000 | 142,000 | ||||
Minimum [Member] | 2009 Plan [Member] | ||||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||||
Vesting period | 1 year | |||||
Maximum [Member] | 2009 Plan [Member] | ||||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||||
Vesting period | 4 years |
Stockholders' Equity (Schedule
Stockholders' Equity (Schedule Of Option Activity) (Details) - $ / shares | 9 Months Ended | 12 Months Ended |
Mar. 31, 2018 | Jun. 30, 2017 | |
Stockholders' Equity [Abstract] | ||
Options, Outstanding at beginning of period | 1,495,573 | |
Options, Granted | 238,815 | |
Options, Exercised | (432,522) | |
Options, Forfeited | ||
Options, Outstanding at end of period | 1,301,866 | 1,495,573 |
Options, Exercise price of granted options | $ 84.98 | |
Options exercisable at end of period | 787,339 | |
Weighted Average Exercise Price, Outstanding at beginning of period | $ 47.09 | |
Weighted Average Exercise Price, Granted | 84.98 | |
Weighted Average Exercise Price, Exercised | 34.92 | |
Weighted Average Exercise Price, Forfeited | ||
Weighted Average Exercise Price, Outstanding at end of period | 58.09 | $ 47.09 |
Weighted Average Exercise Price, Options exercisable at end of period | $ 49.81 | |
Weighted Average Remaining Contractual Term in Years, Outstanding | 4 years 4 months 24 days | 3 years 10 months 24 days |
Stockholders' Equity (Schedul49
Stockholders' Equity (Schedule Of Activity Of Restricted Stock Units) (Details) - Restricted Stock Units (RSUs) [Member] - $ / shares | 9 Months Ended | 12 Months Ended |
Mar. 31, 2018 | Jun. 30, 2017 | |
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||
Restricted Stock Units, Outstanding at beginning of period | 1,906,394 | |
Restricted Stock Units, Granted | 472,158 | |
Restricted Stock Units, Vested | (652,065) | |
Restricted Stock Units, Expired | (8,415) | |
Restricted Stock Units, Forfeited | (58,483) | |
Restricted Stock Units, Outstanding at end of period | 1,659,589 | 1,906,394 |
Weighted Average Grant-Date Fair Value, Outstanding at beginning of period | $ 53.26 | |
Weighted Average Grant-Date Fair Value, Granted | 80.08 | |
Weighted Average Grant-Date Fair Value, Vested | 52.31 | |
Weighted Average Grant-Date Fair Value, Expired | 57.40 | |
Weighted Average Grant-Date Fair Value, Forfeited | 57.40 | |
Weighted Average Grant-Date Fair Value, Outstanding at end of period | $ 62.72 | $ 53.26 |
Weighted Average Remaining Contractual Term in Years, Outstanding | 1 year 10 months 24 days | 1 year 7 months 6 days |
Earnings Per Share (Narrative)
Earnings Per Share (Narrative) (Details) - shares | 3 Months Ended | 9 Months Ended | ||
Mar. 31, 2018 | Mar. 31, 2017 | Mar. 31, 2018 | Mar. 31, 2017 | |
Earnings Per Share [Abstract] | ||||
Stock options and restricted stock units not included in the computation of diluted earnings per share | 239,020 | 12,256 | 125,995 | 415,038 |
Earnings Per Share (Schedule Of
Earnings Per Share (Schedule Of Basic And Diluted Earnings Per Share) (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands | 3 Months Ended | 9 Months Ended | ||
Mar. 31, 2018 | Mar. 31, 2017 | Mar. 31, 2018 | Mar. 31, 2017 | |
Numerator: | ||||
Net income | $ 110,125 | $ 87,823 | $ 205,777 | $ 240,672 |
Denominator: | ||||
Basic weighted-average common shares outstanding | 142,898 | 141,714 | 142,688 | 141,266 |
Effect of dilutive securities: | ||||
Stock options and restricted stock units | 1,087 | 1,010 | 1,207 | 1,097 |
Diluted weighted average shares | 143,985 | 142,724 | 143,895 | 142,363 |
Basic earnings per share | $ 0.77 | $ 0.62 | $ 1.44 | $ 1.70 |
Diluted earnings per share | $ 0.76 | $ 0.62 | $ 1.43 | $ 1.69 |
Fair Value Measurements (Summar
Fair Value Measurements (Summary Of Financial Assets And Liabilities) (Details) - USD ($) $ in Thousands | Mar. 31, 2018 | Jun. 30, 2017 |
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Foreign currency hedging instruments, net | $ 2,760 | |
Foreign currency hedging instruments, net | $ (1,786) | |
Business acquisition contingent consideration | (1,758) | (1,580) |
Level 1 [Member] | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Foreign currency hedging instruments, net | ||
Foreign currency hedging instruments, net | ||
Business acquisition contingent consideration | ||
Level 2 [Member] | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Foreign currency hedging instruments, net | 2,760 | |
Foreign currency hedging instruments, net | (1,786) | |
Business acquisition contingent consideration | ||
Level 3 [Member] | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Foreign currency hedging instruments, net | ||
Foreign currency hedging instruments, net | ||
Business acquisition contingent consideration | $ (1,758) | $ (1,580) |
Fair Value Measurements (Reconc
Fair Value Measurements (Reconciliation For Fair Value Measurements Using Significant Unobservable Inputs) (Details) - USD ($) $ in Thousands | 9 Months Ended | |
Mar. 31, 2018 | Mar. 31, 2017 | |
Fair Value Measurements [Abstract] | ||
Balance at the beginning of the period | $ (1,580) | $ (10,450) |
Changes in fair value included in operating income | (383) | (10,076) |
Payments | 205 | 20,142 |
Foreign currency translation adjustments | 28 | |
Balance at the end of the period | $ (1,758) | $ (356) |
Legal Actions And Contingenci54
Legal Actions And Contingencies (Narrative) (Details) - USD ($) $ in Thousands | 1 Months Ended | |
Mar. 31, 2018 | Jun. 30, 2017 | |
Loss Contingencies [Line Items] | ||
Income taxes payable | $ 124,569 | $ 29,150 |
Australian Taxation Office [Member] | ||
Loss Contingencies [Line Items] | ||
Additional tax liabilities related to assessments | 151,700 | |
Interest related to assessments | $ 38,400 | |
Minimum [Member] | Australian Taxation Office [Member] | ||
Loss Contingencies [Line Items] | ||
Tax year under audit | 2,009 | |
Maximum [Member] | Australian Taxation Office [Member] | ||
Loss Contingencies [Line Items] | ||
Tax year under audit | 2,013 | |
Due April 2018 [Member] | Australian Taxation Office [Member] | ||
Loss Contingencies [Line Items] | ||
Income taxes payable | $ 75,900 |
Legal Actions And Contingenci55
Legal Actions And Contingencies (Summary Of Receivables Sold With Recourse) (Details) - USD ($) $ in Thousands | 9 Months Ended | |
Mar. 31, 2018 | Mar. 31, 2017 | |
Contingent Obligations Under Recourse Provisions [Line Items] | ||
Total receivables sold | $ 72,427 | $ 67,516 |
Full Recourse [Member] | ||
Contingent Obligations Under Recourse Provisions [Line Items] | ||
Total receivables sold | 16,125 | 14,540 |
Limited Recourse [Member] | ||
Contingent Obligations Under Recourse Provisions [Line Items] | ||
Total receivables sold | $ 56,302 | $ 52,976 |
Legal Actions And Contingenci56
Legal Actions And Contingencies (Summary Of Maximum Exposure On Outstanding Receivables Sold With Recourse And Provision) (Details) - USD ($) $ in Thousands | Mar. 31, 2018 | Jun. 30, 2017 |
Contingent Obligations Under Recourse Provisions [Line Items] | ||
Maximum exposure on outstanding receivables | $ 27,688 | $ 27,500 |
Provision for doubtful accounts - recourse receivables | (1,062) | (1,437) |
Full Recourse [Member] | ||
Contingent Obligations Under Recourse Provisions [Line Items] | ||
Maximum exposure on outstanding receivables | 18,274 | 18,068 |
Limited Recourse [Member] | ||
Contingent Obligations Under Recourse Provisions [Line Items] | ||
Maximum exposure on outstanding receivables | $ 9,414 | $ 9,432 |
Derivative Instruments And He57
Derivative Instruments And Hedging Activities (Narrative) (Details) - USD ($) $ in Millions | 9 Months Ended | |
Mar. 31, 2018 | Jun. 30, 2017 | |
Derivative [Line Items] | ||
Notional amount of foreign currency hedging contracts held | $ 601.8 | $ 568.2 |
Foreign Currency Hedging Instruments [Member] | ||
Derivative [Line Items] | ||
Terms of foreign currency hedging contracts, maximum | 3 years | |
Maturity date | Dec. 31, 2019 |
Derivative Instruments And He58
Derivative Instruments And Hedging Activities (Summary Of Amount And Location Of Derivative Financial Instruments) (Details) - Foreign Currency Hedging Instruments [Member] - USD ($) $ in Thousands | Mar. 31, 2018 | Jun. 30, 2017 |
Derivatives, Fair Value [Line Items] | ||
Net foreign currency hedging instruments | $ (1,786) | $ 2,760 |
Other Assets - Current [Member] | ||
Derivatives, Fair Value [Line Items] | ||
Foreign currency hedging instruments, assets | 980 | 2,614 |
Other Assets - Non Current [Member] | ||
Derivatives, Fair Value [Line Items] | ||
Foreign currency hedging instruments, assets | 1,273 | |
Accrued Expenses [Member] | ||
Derivatives, Fair Value [Line Items] | ||
Foreign currency hedging instruments, liabilities | $ (2,766) | $ (1,127) |
Derivative Instruments And He59
Derivative Instruments And Hedging Activities (Summary Of Gains (Losses) Associated With Derivative Financial Instruments) (Details) - Derivatives Not Designated As Hedging Instruments [Member] - USD ($) $ in Thousands | 9 Months Ended | |
Mar. 31, 2018 | Mar. 31, 2017 | |
Derivative Instruments, Gain (Loss) [Line Items] | ||
Gain (loss) recognized in income | $ (2,705) | $ 5,434 |
Foreign Currency Hedging Instruments [Member] | Other, Net [Member] | ||
Derivative Instruments, Gain (Loss) [Line Items] | ||
Foreign currency hedging instruments | (10,013) | 1,812 |
Other Foreign-Currency-Denominated Transactions [Member] | Other, Net [Member] | ||
Derivative Instruments, Gain (Loss) [Line Items] | ||
Other foreign-currency-denominated transactions | $ 7,308 | $ 3,622 |
Restructuring Expenses (Narrati
Restructuring Expenses (Narrative) (Details) - USD ($) $ in Thousands | 3 Months Ended | 9 Months Ended | |||
Jun. 30, 2018 | Mar. 31, 2018 | Mar. 31, 2017 | Mar. 31, 2018 | Mar. 31, 2017 | |
Restructuring Cost and Reserve [Line Items] | |||||
Restructuring expenses | $ 10,922 | $ 7,945 | $ 10,922 | $ 12,358 | |
Employee-related payments | 10,200 | 10,200 | |||
Accrued expenses | $ 3,000 | $ 3,000 | |||
Scenario, Forecast [Member] | |||||
Restructuring Cost and Reserve [Line Items] | |||||
Restructuring expenses | $ 7,000 |
Subsequent Event (Narrative) (D
Subsequent Event (Narrative) (Details) - Subsequent Event [Member] $ in Millions | Apr. 17, 2018USD ($) |
Revolving Credit Facility [Member] | Minimum [Member] | |
Subsequent Event [Line Items] | |
Commitment fees percentage rate on unused portion of credit facility | 0.10% |
Revolving Credit Facility [Member] | Maximum [Member] | |
Subsequent Event [Line Items] | |
Commitment fees percentage rate on unused portion of credit facility | 0.175% |
Revolving Credit Facility [Member] | MUFG Union Bank, N.A. and Westpac Banking Corporation [Member] | |
Subsequent Event [Line Items] | |
Maximum borrowing capacity | $ 800 |
Uncommitted option to increase credit facility | 300 |
Term Credit Agreement [Member] | MUFG Union Bank, N.A. and Westpac Banking Corporation [Member] | |
Subsequent Event [Line Items] | |
Maximum borrowing capacity | $ 200 |
Revolving Credit Facility And Term Credit Agreement [Member] | MUFG Union Bank, N.A. and Westpac Banking Corporation [Member] | |
Subsequent Event [Line Items] | |
Maturity date | Apr. 17, 2023 |
Principal payment | $ 6 |
Frequency of payments | semi-annual |
London Interbank Offered Rate (LIBOR) [Member] | Revolving Credit Facility [Member] | Minimum [Member] | |
Subsequent Event [Line Items] | |
Credit facility interest rate equal to reference rate plus | 0.75% |
London Interbank Offered Rate (LIBOR) [Member] | Revolving Credit Facility [Member] | Maximum [Member] | |
Subsequent Event [Line Items] | |
Credit facility interest rate equal to reference rate plus | 1.50% |
Base Rate [Member] | Revolving Credit Facility [Member] | Minimum [Member] | |
Subsequent Event [Line Items] | |
Credit facility interest rate equal to reference rate plus | 0.00% |
Base Rate [Member] | Revolving Credit Facility [Member] | Maximum [Member] | |
Subsequent Event [Line Items] | |
Credit facility interest rate equal to reference rate plus | 0.50% |